Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: A final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group

Leukemia

Volumn 21, Issue 11, 2007, Pages 2258-2263

  Tomizawa, D ^a   Koh, K ^b   Sato, T ^c   Kinukawa, N ^d   Morimoto, A ^e   Isoyama, K ^f   Kosaka, Y ^g   Oda, T ^h   Oda, M ⁱ   Hayashi, Y ^j   Eguchi, M ^k   Horibe, K ^l   Nakahata, T ^m   Mizutani, S ^a   Ishii, E ⁿ  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^f SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^g Hyogo Children's Hospital   (Japan)

^h National Hospital Organization   (Japan)

ⁱ OKAYAMA UNIVERSITY   (Japan)

^j Gumna Children S Medical Center   (Japan)

^k DOKKYO MEDICAL UNIVERSITY   (Japan)

^l NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^m KYOTO UNIVERSITY   (Japan)

ⁿ EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; GROWTH HORMONE; METHOTREXATE; MIXED LINEAGE LEUKEMIA PROTEIN; TACROLIMUS; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; GENE REARRANGEMENT; GRAFT VERSUS HOST REACTION; GROWTH DISORDER; HUMAN; HUMAN CELL; INFANT; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME;

EID: 35548995884     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404903     Document Type: Article

References (30)

1. Pui C-H, Evans WE. Treatment ot acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
2. Dödelmann M, Reiter A, Borkhardt A, Ludwig W-D, Götz N, Viehrtiann S et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999 ; 94: 1209-1217.
3. FerstOr A, Benoit Y, Francotte N, Dresse M-F, Uyttebroeck A, Plouvier E et al. Treatment outcome in infant acute lymphoblastic leukemia. Blood 2000; 95: 2729-2731.
4. Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 1999; 17: 445-455.
5. Hilden JIM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, Heerema NA et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: Report on CCG 1953 from the Children's Oncology Group. Blood 2006; 108: 441-451.
6. Chessels JM, Harrison CJ, Watson SL, Vora AJ, Richards SM. Treatment of infants with lymphoblastic leukaemia: Results of the UK Infant Protocols 1987-1999. Br J Haematol 2002; 117: 306-314.
7. Frankel LS, Ochs J, Shuster JJ, Dubowy R, Bowman WP, Hockenberry-Eaton M et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol 1997; 19: 35-42.
8. Silverman LB, Mclean TW, Gelber RD, Donnelly MJ, Gilliland DG, Tarbell NJ et al. Intensified therapy for infants with acute lymphoblastic leukemia: Results from the Dana-Farber Cancer Institute Consortium. Cancer 1997; 80: 2285-2295.
9. Crist W, Pullen J, Boyett J, Falletta J, van Eys J, Borowitz M et al Clinical and biologic features predict a poor prognosis in acute lymphoblastic leukemias in infants: Pediatric Oncology Group study. Blood 1986; 67: 135-140.
10. Dinndorf PA, Reaman GH. Acute lymphoblastic leukemia in infants: evidence of B cell origin of disease by use of monoclonal antibody phenotyping. Blood 1986; 68: 975-978.
11. Pui C-H, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia 1995; 9: 762-769.
12. Heerema NA, Arthur DC, Sather H, Albo V, Feusner J, Lange BJ et al Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: Impact of the 11q23 breakpoint on outcome: A report of the Children's Cancer Group. Blood 1994; 83: 2274-2284.
13. Chen CS, Sorensen PH, Domer PH, Reaman GH, Korsmeyer SJ, Heerema NA et al. Molecular rearrangements on chromosome I I q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 1993; 81: 2386-2393.
14. Pui C-H, Behm FG, Downing JR, Hancock ML, Shurtleff SA, Ribeiro RC et al. 11q23/MLL rearrangement confers a poor Supplementary Information accompanies the paper on the Leukemia prognosis in miants with acute lymphoblastic leukemia. J clin Oncol 1994; 12: 909-915.
15. Taki T, Ida K, Bessho F, Hanada R, Kikuchi A, Yamamoto K et al. Frequency and clinical sigfiificance of the MLL gene rearrangements in infant acute leukemia. Leukemia 1996, 10: 1303-1307.
16. Isoyama K, Eguchi M, Hibi S, Kinukawa N, Ohkawa H, Kawasaki H et al Risk-directed treatment of infant acute lymphoblast leukaernia based on early assessment of MLL gene status: Results of the Japan Infant Leukaemia Study (MLL96). Br j Haematol 2002; 118: 999-1010.,
17. Kosaka Y, Koh K, Kinukawa N, Wakazono Y, Isoyama K, Oda T et ..al. infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 2004; 104: 3527-3534
18. Nagayama J, Tomizawa D, Koh K, Nagatoshi Y, Hotta N, Kishimoto T et al. Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: Results from the Japan Infant Leukemia Study Group. Blood 2006; 107: 463-4665.
19. Pui C-H, Gaynon PS, Boyett JM, Chessells JM, Baruchel A; Kamps W et al. Outcome of treatment in childhood acute lymphoblastic leukemia with rearrangement of the IIq23 chromosornal !egion. Lancet 2002;.359: 1909-1915. .
20. Marco F, Bureo E, Ortega JJ Badell l; Verdaguer A, Martinez A et al High-survival rate in infantacute leukemia treated with- early high-dose chemotherapy ani stem-cell support. Grupo Espanol de Transplante de Medula Osea en Ninos. J Clin Oncol 2000; 18: 3256-3261.
21. Copelan EA, Kapoor N, Murcek M, Theil K, Tutschka PJ. Marrow transplantation following busulfan and cyclophosphamide as treatment for translocation (4;11) acute leukerrida. Br j Haemajv 1988; 70: 127-128.
22. Bordigoni P, Benz-Lemoine E, Vannier JP, Fischer A. Bone marrow transplantation following busulfan, cyclophosphamide and high dose cytosine-arabinoside as treatment for infants with translocation (4;11) acute leukaemia. Br J Haematol 1989; 72: 293-294.
23. Emminger W, Emminger-Schmidmeier W, Haas OA,Urban C, Ambros P, Petets C et al.reatment of infant leukemia with busulfan, cyclophosphamidenetoposide and bone marrow trans- plantation. Bone Marrow Transplant 1992; 9: 313-318.
24. von Bueltzingsloewen A, Esperou-Bourdeau H, Souillet G, Demeocq F, Mechinaud-Lacroix F, Michel G et al. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: A Cooperative Study of the Société Française de Greffe de Moelle. Bone Marrow Transplant 1995; 16: 521-527.
25. Pirich L, Haut P, Morgan E, Marymount M, Kletzel M. Total'body irradiation, cyclophosphamide, and etaposide with stem cell transplant as treatment for infants with acute lymphocytic leukemia. Med Pediatr Oncol 1999; 32: 1-6.
26. Leung W, Pitts N, Burnette K, Cunningham JM, Horwitz EM, Benaim,E et al. Allogeneic bonp marrow transplantation for infants with acute leukemia or myelodysplastic syndrome. Bone Marrow Transplant 2001; 27: 717-7,22.
27. Sanders JE, Im H-J, Hoffmeister PA, Gooley TA, Woolfrey AE, Carpenter PA et al Allogeneic hematopoietic cell transplantation for infant with acute lymphoblastic leukemia. Blood 2005; 105: 3749-3756.
28. Pieters R, den Boer,ML, Durian M, Janka G, Schmiegelow K, Kaspers GJ et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia-implications for treatment of infants. Leukemia 1998; 12: 1344-1348.
29. Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 2005; 106: 2484-2490.
30. Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 2005; 105: 812-820.